Source: BEFREE

Gene Disease Score gda Association Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 354
Gene Symbol: KLK3
KLK3
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.200 Biomarker BEFREE Widespread prostate-specific antigen (PSA) testing notably increased the number of prostate cancer (PCa) diagnoses. 28555004

2018

Entrez Id: 354
Gene Symbol: KLK3
KLK3
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.200 Biomarker BEFREE The incidence of low-risk prostate cancer (PCa) has increased as a consequence of prostate-specific antigen testing. 28318726

2018

Entrez Id: 354
Gene Symbol: KLK3
KLK3
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.200 Biomarker BEFREE Prostate cancer (PCa) diagnosis using patient urine samples represents a non-invasive and more convenient method than the conventional biopsy and prostate-specific antigen (PSA) test. 29491074

2018

Entrez Id: 675
Gene Symbol: BRCA2
BRCA2
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.200 Biomarker BEFREE Inherited mutations in DNA-repair genes such as BRCA2 are associated with increased risks of lethal prostate cancer. 28789927

2018

Entrez Id: 6581
Gene Symbol: SLC22A3
SLC22A3
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.200 Biomarker BEFREE EMT circulating tumor cells detected by cell-surface vimentin are associated with prostate cancer progression. 28521303

2018

Entrez Id: 354
Gene Symbol: KLK3
KLK3
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.200 Biomarker BEFREE Besides clinical stage and Gleason score, risk-stratification of prostate cancer in the pretherapeutic setting mainly relies on the serum PSA level. 28923030

2018

Entrez Id: 6581
Gene Symbol: SLC22A3
SLC22A3
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.200 Biomarker BEFREE Oncogenic miR-210-3p promotes prostate cancer cell EMT and bone metastasis via NF-κB signaling pathway. 28693582

2018

Entrez Id: 354
Gene Symbol: KLK3
KLK3
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.200 Biomarker BEFREE Sensitivity of HOXB13 as a Diagnostic Immunohistochemical Marker of Prostatic Origin in Prostate Cancer Metastases: Comparison to PSA, Prostein, Androgen Receptor, ERG, NKX3.1, PSAP, and PSMA. 28555048

2018

Entrez Id: 354
Gene Symbol: KLK3
KLK3
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.200 Biomarker BEFREE Two key issues in prostate cancer (PCa) that demand attention currently are the need for a more precise and minimally invasive screening test owing to the inaccuracy of prostate-specific antigen and differential diagnosis to distinguish advanced vs. indolent cancers. 28527622

2018

Entrez Id: 675
Gene Symbol: BRCA2
BRCA2
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.200 GeneticVariation BEFREE BRCA2 mutations should be screened early and routinely as markers of poor prognosis: evidence from 8,988 patients with prostate cancer. 28410213

2018

Entrez Id: 6581
Gene Symbol: SLC22A3
SLC22A3
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.200 Biomarker BEFREE Long noncoding RNA PVT1 promotes EMT via mediating microRNA-186 targeting of Twist1 in prostate cancer. 29452232

2018

Entrez Id: 354
Gene Symbol: KLK3
KLK3
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.200 GeneticVariation BEFREE T2E transcripts were detected in 31.7% (n=20) of the patients examined, and this was significantly associated with subsequent detection of PC in ASAP patients with a prostate specific antigen (PSA) level of 4-10ng/ml (p=0.045). 29277318

2018

Entrez Id: 354
Gene Symbol: KLK3
KLK3
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.200 AlteredExpression BEFREE Highly efficient target therapy is urgently needed for prostate cancer with overexpression of γ-seminoprotein (γ-SM). 28529067

2017

Entrez Id: 354
Gene Symbol: KLK3
KLK3
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.200 GeneticVariation BEFREE Our results suggest that rs4962416, previously associated only with prostate cancer, is also associated with PSA levels, with 12% increase for each copy of the minor allele C. The study enabled the replication of the effect for the majority of previously reported genetic variants in a set of clinically relevant prostate cancers. 26773531

2017

Entrez Id: 354
Gene Symbol: KLK3
KLK3
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.200 Biomarker BEFREE Androgen/AR is the primary contributor to prostate cancer (PCa) progression by regulating Prostate Specific Antigen (PSA) gene transcription. 28199985

2017

Entrez Id: 354
Gene Symbol: KLK3
KLK3
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.200 GeneticVariation BEFREE Single-nucleotide polymorphism rs1058205 of KLK3 is associated with the risk of prostate cancer: A case-control study of Han Chinese men in Northeast China. 28272245

2017

Entrez Id: 6581
Gene Symbol: SLC22A3
SLC22A3
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.200 Biomarker BEFREE SOX4 induces tumor invasion by targeting EMT-related pathway in prostate cancer. 28466783

2017

Entrez Id: 354
Gene Symbol: KLK3
KLK3
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.200 Biomarker BEFREE Differential blood-based diagnosis between benign prostatic hyperplasia and prostate cancer: miRNA as source for biomarkers independent of PSA level, Gleason score, or TNM status. 26831660

2017

Entrez Id: 354
Gene Symbol: KLK3
KLK3
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.200 AlteredExpression BEFREE In a previous population-based study on 3369 European men with self-reported prostate cancer (PCa), it was shown that androgen receptor (AR) haplotype designated H2 was associated with high levels of serum PSA (prostate-specific antigen) concentration, and, at the same time, with low risk for PCa. 28176139

2017

Entrez Id: 354
Gene Symbol: KLK3
KLK3
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.200 Biomarker BEFREE Background One of the kallikrein genes ( KLK3) encodes prostate-specific antigen, a key biomarker for prostate cancer. 27555663

2017

Entrez Id: 354
Gene Symbol: KLK3
KLK3
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.200 Biomarker BEFREE In this study we compared the levels of PCa-specific biomarkers (PCA3 and ERG) and KLK3 as prostate-specific reference gene in three urine substrates-whole urine, urinary sediment (cell pellet) and exosomes-and evaluated the influence of performing a digital rectal examination (DRE) prior to urine sampling. 26630694

2017

Entrez Id: 354
Gene Symbol: KLK3
KLK3
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.200 AlteredExpression BEFREE Screening for increased levels of prostate-specific antigen (PSA) has allowed early detection of a large majority of prostate cancer (PCa) cases. 26711283

2017

Entrez Id: 675
Gene Symbol: BRCA2
BRCA2
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.200 GeneticVariation BEFREE Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores. 28448241

2017

Entrez Id: 675
Gene Symbol: BRCA2
BRCA2
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.200 Biomarker BEFREE Increased risk of male cancer and identification of a potential prostate cancer cluster region in BRCA2. 26360800

2016

Entrez Id: 675
Gene Symbol: BRCA2
BRCA2
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.200 GeneticVariation BEFREE Prostate cancer in a man with a BRCA2 mutation and a personal history of bilateral breast cancer. 25112434

2016